MX2022000429A - Telmisartan para el tratamiento de la enfermedad renal cronica en perros. - Google Patents

Telmisartan para el tratamiento de la enfermedad renal cronica en perros.

Info

Publication number
MX2022000429A
MX2022000429A MX2022000429A MX2022000429A MX2022000429A MX 2022000429 A MX2022000429 A MX 2022000429A MX 2022000429 A MX2022000429 A MX 2022000429A MX 2022000429 A MX2022000429 A MX 2022000429A MX 2022000429 A MX2022000429 A MX 2022000429A
Authority
MX
Mexico
Prior art keywords
telmisartan
treatment
dogs
kidney disease
chronic kidney
Prior art date
Application number
MX2022000429A
Other languages
English (en)
Spanish (es)
Inventor
Anne Michelle Traas
De Moura Lourenco Bianca Natália Ferreira
Kate Elizabeth Creevy
Scott Alan Brown
Coleman Amanda Erickson
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of MX2022000429A publication Critical patent/MX2022000429A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022000429A 2019-07-09 2020-04-30 Telmisartan para el tratamiento de la enfermedad renal cronica en perros. MX2022000429A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962871752P 2019-07-09 2019-07-09
PCT/US2020/030579 WO2021006941A1 (en) 2019-07-09 2020-04-30 Telmisartan for the treatment of chronic kidney disease in dogs

Publications (1)

Publication Number Publication Date
MX2022000429A true MX2022000429A (es) 2022-04-25

Family

ID=70775531

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000429A MX2022000429A (es) 2019-07-09 2020-04-30 Telmisartan para el tratamiento de la enfermedad renal cronica en perros.

Country Status (10)

Country Link
US (1) US20220218671A1 (enExample)
EP (1) EP3996705A1 (enExample)
JP (2) JP2022540074A (enExample)
KR (1) KR20220054291A (enExample)
CN (1) CN114450004A (enExample)
AU (1) AU2020311280B2 (enExample)
BR (1) BR112022000315A2 (enExample)
CA (1) CA3142876A1 (enExample)
MX (1) MX2022000429A (enExample)
WO (1) WO2021006941A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3996709A1 (en) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan for the treatment of hypertension in dogs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ759782A (en) 2017-07-07 2023-06-30 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats

Also Published As

Publication number Publication date
JP2025120167A (ja) 2025-08-15
BR112022000315A2 (pt) 2022-02-22
TW202116305A (zh) 2021-05-01
US20220218671A1 (en) 2022-07-14
AU2020311280B2 (en) 2026-05-07
KR20220054291A (ko) 2022-05-02
WO2021006941A1 (en) 2021-01-14
CN114450004A (zh) 2022-05-06
EP3996705A1 (en) 2022-05-18
AU2020311280A1 (en) 2022-02-24
JP2022540074A (ja) 2022-09-14
CA3142876A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
MX384234B (es) Uso de pridopidina para el tratamiento de enfermedad de huntington.
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX390627B (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
NZ714963A (en) Compositions and methods for treating anemia
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
NZ602029A (en) Use of meloxicam for the long-term treatment of kidney disorders in cats
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
NO20082536L (no) Behandling av kronisk nyresykdom(CKD)individer ved bruk av lantanforbindelser
EA201390618A1 (ru) Режимы дозирования при лечении офтальмологического сосудистого заболевания
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX381526B (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal crónica.
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
EA202190398A1 (ru) Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4
AR122933A1 (es) Métodos para tratar la enfermedad cardiovascular
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
CL2021003303A1 (es) Tratamiento para sinucleinopatías.